Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426)
Source: View publication →
The KEYNOTE-426 phase 3 trial demonstrated that the combination of pembrolizumab and axitinib provides superior overall survival, progression-free survival, and objective response rates compared to sunitinib monotherapy as a first-line treatment for advanced clear cell renal cell carcinoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
The KEYNOTE-426 study established the combination of an immune checkpoint inhibitor (pembrolizumab) and a VEGF receptor tyrosine kinase inhibitor (axitinib) as a foundational standard of care for first-line advanced renal cell carcinoma, significantly improving long-term survival outcomes compared to traditional VEGFR-TKI monotherapy.
Historical Context
Prior to this trial, sunitinib was the established standard of care for previously untreated metastatic renal cell carcinoma. KEYNOTE-426 was a landmark study that validated the strategy of combining immunotherapy with anti-angiogenic therapy, changing the therapeutic paradigm for advanced kidney cancer.
Guided Discussion
High-yield insights from every perspective
How does the pharmacological synergy between a PD-1 inhibitor like pembrolizumab and a VEGF receptor tyrosine kinase inhibitor like axitinib contribute to the improved outcomes observed in renal-cell carcinoma?
Key Response
This question connects immunology with vascular biology. Pembrolizumab blocks the PD-1/PD-L1 pathway to restore T-cell activity against tumor cells, while axitinib inhibits VEGF receptors to reduce tumor angiogenesis. Crucially, VEGF inhibition also reduces the presence of immunosuppressive cells (like MDSCs and Tregs) in the tumor microenvironment, potentially enhancing the efficacy of the checkpoint inhibitor.
In a patient treated with the pembrolizumab-axitinib combination who presents with a sudden Grade 3 elevation in ALT/AST, what clinical strategy should be used to differentiate between drug-induced liver injury and immune-mediated hepatitis?
Key Response
Differentiating these is vital for management. Axitinib has a short half-life (approx. 2-5 hours); therefore, the recommended approach is to withhold the TKI first. If transaminases improve rapidly within 24-48 hours, axitinib is likely the culprit. If they remain elevated or rise, it suggests pembrolizumab-induced immune-mediated hepatitis requiring systemic corticosteroids.
The KEYNOTE-426 trial demonstrated benefit across all IMDC risk groups. However, how should the non-significant OS hazard ratio in the favorable-risk subgroup at the initial analysis influence the choice between IO-TKI and TKI-monotherapy for this specific population?
Key Response
In the favorable-risk group, sunitinib performs exceptionally well. While the combination showed a superior objective response rate (ORR), the OS benefit was less pronounced initially (HR 0.64, 95% CI 0.24-1.68). Fellows must weigh the high response rate of the combination against the potential for long-term toxicity, especially since favorable-risk patients may live long enough to experience cumulative side effects.
With the emergence of multiple frontline IO-TKI combinations (e.g., Lenvatinib-Pembrolizumab, Cabozantinib-Nivolumab), what specific trial characteristics of KEYNOTE-426 make Pembrolizumab-Axitinib a preferred 'workhorse' regimen in clinical practice?
Key Response
KEYNOTE-426 was the first to show a triple benefit (OS, PFS, and ORR) over sunitinib. Its preference often stems from the familiarity and titratability of axitinib. Unlike lenvatinib or cabozantinib, axitinib's short half-life allows for rapid dose adjustments or interruptions to manage toxicities, which is a significant teaching point for managing treatment-emergent adverse events in a busy clinic.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The KEYNOTE-426 trial utilized a dual primary endpoint of OS and PFS in the intention-to-treat population. What are the statistical risks associated with multiplicity in this design, and how did the investigators maintain the family-wise error rate?
Key Response
The study used a hierarchical testing strategy and alpha-splitting (using a Maurer-Bretz procedure) to control for Type I error across multiple endpoints and interim analyses. Understanding how the alpha is redistributed after an endpoint reaches significance is critical for evaluating the validity of secondary outcomes and the robustness of the overall trial conclusions.
Given that sunitinib was the comparator, how does the high rate of subsequent anti-VEGF or immune-oncology therapy in the control arm (over 50%) impact the interpretation of the Overall Survival benefit, and what sensitivity analyses would a reviewer demand to address this?
Key Response
A tough reviewer would worry that 'crossover' or effective second-line therapies might mask the true benefit of the experimental arm. The editor would look for sensitivity analyses like the Rank-Preserving Structural Failure Time (RPSFT) model or Censoring at Crossover to estimate what the OS benefit would have been if the control group had not received subsequent life-prolonging therapies.
How do the results of KEYNOTE-426 specifically conflict with or support the CheckMate 214 findings regarding the treatment of 'favorable-risk' patients, and how should this be reflected in updated NCCN or EAU guidelines?
Key Response
CheckMate 214 (Nivo/Ipi) did not show a benefit over sunitinib in favorable-risk patients, leading guidelines to recommend TKI monotherapy or IO-TKI for that group. KEYNOTE-426 showed a significant ORR and PFS benefit across all groups, including favorable-risk. Therefore, guidelines (like NCCN) now list Pembro-Ax as a Category 1 'Preferred' option for all risk categories, whereas Nivo-Ipi is reserved for intermediate/poor risk.
Clinical Landscape
Noteworthy Related Trials
CheckMate 214
Tested
Nivolumab plus ipilimumab
Population
Advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Overall survival and progression-free survival in patients with intermediate or poor risk
JAVELIN Renal 101
Tested
Avelumab plus axitinib
Population
Advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival in patients with PD-L1 positive tumors
IMmotion151
Tested
Atezolizumab plus bevacizumab
Population
Advanced renal-cell carcinoma
Comparator
Sunitinib
Endpoint
Progression-free survival and overall survival in PD-L1 positive patients
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis